Investment case
Elevance Health, Inc.
ELEV · 16 developments mapped · last assessed 2026-09-18
Market Ontology has mapped 16 macro, policy, and market developments to Elevance Health, Inc. since 2026-09-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ELEV yet, so no modelled value is shown. The ELEV valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ELEV on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Centene improves Medicare health benefit ratio to 89.5% amid footprint reset
Sector-wide sentiment improvement due to positive operational signals from a peer, suggesting broader industry trends.
· Moves sector profitability outlook, investor sentiment towards managed care
- Main threat
Centene posts Q2 adjusted EPS of $2.51 as Medicaid rolls face 8%-9% 2026 decline
Second-order effect; industry-wide Medicaid enrollment trends could impact ELEV's Medicaid segment.
· Moves medicaid membership growth rates, segment specific medical loss ratio (mlr)
- Open question
Centene Targets Medicare Advantage Margin Recovery as Q2 Medical Loss Ratio Hits 89.5%
Elevance Health operates a significant health benefits business, including Medicare Advantage plans. It is likely subject to similar margin pressures and repricing dynamics as its peers.
· Moves sector wide margin stability, competitive landscape
What changed, by assumption
- 2026-09-12Centene improves Medicare health benefit ratio to 89.5% amid footprint reset
- 2026-09-12Centene Targets Medicare Advantage Margin Recovery as Q2 Medical Loss Ratio Hits 89.5%
- 2026-09-18Centene posts $2.51 Q2 EPS as Medicaid rolls shrink 8%-9% in 2026
- 2026-09-18Centene posts Q2 adjusted EPS of $2.51 as Medicaid rolls face 8%-9% 2026 decline
- 2026-09-16Centene Corporation Reaffirms Full Year 2026 EPS Guidance
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-18 | Centene posts $2.51 Q2 EPS as Medicaid rolls shrink 8%-9% in 2026 | watch | 3-12m | 0.40 |
| 2026-09-18 | Centene posts Q2 adjusted EPS of $2.51 as Medicaid rolls face 8%-9% 2026 decline | Bearish | 3-12m | 0.40 |
| 2026-09-16 | Centene Corporation Reaffirms Full Year 2026 EPS Guidance | watch | 1-3m | 0.30 |
| 2026-09-13 | Centene Improves Medicare HBR to 89.5% via Footprint Simplification | mixed | 3-12m | 0.30 |
| 2026-09-13 | Centene Targets 2027 Medicare Advantage Breakeven as Health Benefit Ratio Hits 89.5% | mixed | 3-12m | 0.30 |
| 2026-09-13 | Centene Targets Medicare Advantage Breakeven After Q2 Benefit Ratio Hits 89.5% | mixed | 1-3m | 0.30 |
| 2026-09-13 | Centene Restructures Medicare Advantage Footprint as Q2 Health Benefits Ratio Reaches 89.5% | mixed | 3-12m | 0.20 |
| 2026-09-12 | Centene Medicare benefits ratio recovers to 89.5% aiming for 2027 breakeven | mixed | 3-12m | 0.30 |
| 2026-09-12 | Centene Medicare Health Benefits Ratio Improves to 89.5% in Managed Care Overhaul | mixed | 1-3m | 0.20 |
| 2026-09-12 | Centene Medicare health benefits ratio improves to 89.5% in Q2 2026 | mixed | 3-12m | 0.20 |
| 2026-09-12 | Centene improves Medicare health benefit ratio to 89.5% amid footprint reset | Bullish | 1-3m | 0.50 |
| 2026-09-12 | Centene Targets Medicare Advantage Margin Recovery as Q2 Medical Loss Ratio Hits 89.5% | watch | 1-3m | 0.50 |